Gilde Investment Management
Pieris raises fifth funding round
Company previously raised €43m in growth capital
Gilde Healthcare et al. invest £10m in Levicept
Company will use the funding to carry out its first clinical study
VC-backed ProQR raises $97.5m in IPO
Listed Dutch biotech develops drugs designed for the treatment of genetic disorders
Gilde Healthcare leads €12.2m AM-Pharma round
Deal marks company's fifth funding round
EdRip et al. sell Sapiens in trade sale
Medtronics buys business in an all-cash transaction
VC-backed ProQR files for $75m IPO
Sofinnova is company's largest shareholder
Gilde acquires Axa-Stenman
Acquisition marks company's second time under Gilde ownership
Deal in focus: uniQure raises $91.8m in IPO
Netherlands-based uniQure’s debut on the Nasdaq marks one of the latest in a string of European venture capital-backed biotechs flocking to the US markets, but the lack of activity in Europe's public markets does not necessarily equate to a slowdown...
VC-backed uniQure raises $91.8m in IPO
Venture capital-backed Dutch gene therapy company uniQure raised well above its original expectation in its listing on the Nasdaq, bagging $91.8m.
Gilde acquires Viroclinics
Gilde Healthcare Services has acquired a majority stake in Viroclinics Biosciences, a Netherlands-based virology contact research organisation (CRO).
VC-backed uniQure files $75m IPO
Dutch gene therapy company uniQure, backed by several venture capital firms, plans on raising up to $75m in its IPO on the Nasdaq.
Gilde Healthcare closes fund on €145m
Gilde Healthcare Partners has held the final close of its transatlantic life sciences venture fund, Gilde Healthcare III (GHC III), on its target of €145m.
VC-backed uniQure to float
Dutch gene therapy company uniQure, backed by several venture capital firms, has filed a confidential F-1 form with the US Securities and Exchange Commission (SEC) for a potential IPO.
Acacia Pharma raises £15m in series-B
Acacia Pharma, a UK-based cancer-focused pharmaceutical company, has raised £15m in a series-B funding round from a consortium including both new and existing investors.
VC-backed Profibrix sold to big pharma
Index Ventures, Gilde Healthcare Partners, Vesalius Biocapital and Inkef Capital have sold Dutch biotech firm Profibrix to The Medicines Company for a total consideration of $240m.
HG International trades hands between Gilde funds
Gilde Equity Management Benelux (GEM) has sold Dutch cleaning products supplier HG International BV to the GP's sister division, Gilde Buyout Partners (GBP).
PPM Oost sells Pharmaline to Gilde Healthcare Partners
PPM Oost has sold its stake in Dutch medical supplies company Pharmaline to Gilde Healthcare Partners.
Dutch GPs eye Belgian printing company Xeikon
Gilde and Waterland Private Equity are said to be circling Belgian digital printing company Xeikon, according to local press.
Gimv invests £5.7m in series-B round for Prosonix
Gimv has committed £5.7m to the second closing of a series-B financing round, now totalling £17.1m, for UK-based pharma Prosonix.
Symphogen receives second tranche of €100m investment
Danish biotech company Symphogen has received a second tranche from the €100m investment it received in 2011.
unquote" regulation update: Dodd-Frank
In this week's unquote" regulation update, Anneken Tappe looks at the latest developments regarding the Dodd-Frank Act.
Gilde acquires Sovitec from Value Enhancement Partners
Gilde Buyout Partners has bought Belgian manufacturing business Sovitec from Dutch private equity firm VEP.
unquote" regulation update: Basel III
In this week's unquote" regulation update, Anneken Tappe looks at the latest developments regarding Basel III.
Novasep in €310m recap
French specialty chemicals company Novasep has completed its €310 recapitalisation, to which the FSI and Azulis Capital have contributed €33m in equity.